Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

Pharmaceutical company Moderna ( NASDAQ: MRNA) is set to report its first quarter earnings results on Thursday, May 1st, ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The ...

As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.Amid headlines about rising cases of measles, falling vaccination rates and growing vaccine ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

Explosive new research from MIT indicates a troubling link between COVID-19 mRNA vaccines and a shocking rise in all-cause mortality rates. A collaboration between distinguished scientists from ...